The CCL2 expression profile points to an important role in myocytotoxicity directed against the muscle fibers in PM/IBM, as well as to a role in the endotheliopathy associated with DM, and makes it an amenable target for treating different IIM subgroups. This evidence concerns the gene CCL2 and dermatomyositis.